PHIOW - Phio Pharmaceuticals surges 52% on data for RNAi compound for cancer

Shares of microcap Phio Pharmaceuticals (PHIO) have skyrocketed 52% in Friday afternoon trading after releasing preclinical data on an RNAi compound for tumors that aims to enhance the efficacy of anti-PD-1 antibody therapies. The candidate, PH-894, targets bromodomain-containing protein 4 ("BRD4"). Data from in vivo studies showed that PH-894 inhibits tumor growth in both PD-1 inhibition responsive and PD-1 inhibition insensitive models. Strong antitumor efficacy was seen in directly treated as well as distal, untreated tumors. Also, PH-894 improved the antitumor efficacy of anti-PD-1 antibody therapy for locally treated and untreated distal tumors. Check out Phio's (PHIO) 2021 full-year financial results.

For further details see:

Phio Pharmaceuticals surges 52% on data for RNAi compound for cancer